Last reviewed · How we verify
STP705
At a glance
| Generic name | STP705 |
|---|---|
| Also known as | STP705 Powder for Injection, COTSIRANIB, STP705 POWDER FOR INJECTION |
| Sponsor | Sirnaomics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy (PHASE1)
- A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence (PHASE2)
- Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma (PHASE2)
- Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC (PHASE1, PHASE2)
- A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC (PHASE2)
- A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty (PHASE1)
- Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars (PHASE1, PHASE2)
- Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STP705 CI brief — competitive landscape report
- STP705 updates RSS · CI watch RSS
- Sirnaomics portfolio CI